KCS Wealth Advisory’s Bristol-Myers Squibb BMY Stock Holding History

KCS Wealth Advisory’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.4M	Sell	24,038 -2,459	-9%	-$151K	0.59%	48
2023 Q2	$1.69M	Buy	26,497 +1,296	+5%	+$86.9K	0.59%	49
2023 Q1	$1.75M	Buy	25,201 +792	+3%	+$55.9K	0.66%	43
2022 Q4	$1.76M	Buy	24,409 +203	+0.8%	+$15.3K	0.73%	45
2022 Q3	$1.72M	Sell	24,206 -1,024	-4%	-$74.3K	0.79%	43
2022 Q2	$1.94M	Buy	25,230 +660	+3%	+$50.3K	0.86%	38
2022 Q1	$1.79M	Buy	24,570 +1,917	+8%	+$129K	0.83%	46
2021 Q4	$1.41M	Buy	22,653 +1,356	+6%	+$79.5K	0.57%	61
2021 Q3	$1.26M	Buy	21,297 +1,880	+10%	+$124K	0.6%	60
2021 Q2	$1.3M	Buy	19,417 +2,409	+14%	+$157K	0.61%	56
2021 Q1	$1.07M	Buy	17,008 +2,443	+17%	+$152K	0.55%	67
2020 Q4	$903K	Buy	14,565 +1,564	+12%	+$96.2K	0.6%	65
2020 Q3	$784K	Buy	13,001 +477	+4%	+$28.7K	0.63%	67
2020 Q2	$736K	Buy	12,524 +1,322	+12%	+$79.1K	0.61%	66
2020 Q1	$624K	Buy	11,202 +2,266	+25%	+$139K	0.63%	61
2019 Q4	$574K	Buy	+8,936	New	+$512K	0.43%	97

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

KCS Wealth Advisory's BMY Position: Q3 2023 in Review

KCS Wealth Advisory reduced its Bristol-Myers Squibb (BMY) stake by 9.3% in Q3 2023, selling an estimated $151K and leaving 24,038 shares worth $1.4M. The position accounts for 0.59% of the portfolio, ranked #48.

KCS Wealth Advisory first reported a position in BMY in Q4 2019 and has held it in 16 quarters since. The position peaked at $1.94M in Q2 2022. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

KCS Wealth Advisory held 24,038 shares of Bristol-Myers Squibb worth $1.4M as of Q3 2023.
KCS Wealth Advisory sold 2,459 Bristol-Myers Squibb shares in Q3 2023, an estimated $151K.
Bristol-Myers Squibb made up 0.59% of KCS Wealth Advisory's portfolio in Q3 2023, its #48 holding.
KCS Wealth Advisory first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 16 quarters since.
KCS Wealth Advisory's Bristol-Myers Squibb position peaked at $1.94M in Q2 2022.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on KCS Wealth Advisory's 13F filing for Q3 2023, filed 3 Nov 2023.